EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma
Mon, 1st Mar 2021 16:41
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:
Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - Moves Chief Investment Officer Richard Pye to chief financial officer and executive director, while interim CFO Michael Norris moves to non-executive director, both from last Friday. Norris has been interim CFO since March last year. Additionally, Geoff Race joins the board as non-executive director. Race is co-founder and CFO of Nasdaq-listed biopharmaceutical company Minerva Neurosciences Inc.
4d Pharma PLC hires veteran US finance chief and board director ahead of NASDAQ listing
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis
Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ( AI ) and drug discovery linking together generative chemistry and biology for the first time to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis ( IPF ) and be validated with multiple human cell and animal model experiments.
Often found implicated in a wide range of diseases and multiple organs such as lung, liver and kidney, IPF addresses a very broad medical need that affects hundreds of thousands of individuals worldwide.
The pinnacle of the deep learning revolution can be pinged to 2014 when deep learning systems accelerated by NVIDIA GPUs and AI software started outperforming humans in image recognition and generative adversarial networks were invented. It is also the year when we started the company. In 2016 we demonstrated that a deep learning system can identify a n
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence
HONG KONG, Feb. 24, 2021 /PRNewswire/ Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ( AI ) and drug discovery - linking together generative chemistry and biology for the first time - to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis
( IPF ) and be validated with multiple human cell and animal model experiments. Often found implicated in a wide range of diseases and multiple organs such as lung, liver and kidney, IPF addresses a very broad medical need that affects hundreds of thousands of individuals worldwide.
The
Cri-Du-Chat Syndrome Treatment Market research report thoroughly explains each and every aspect related to the Global Cri-Du-Chat Syndrome Treatment Market, which facilitates the report’s reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.
Cri-Du-Chat Syndrome Treatment Market Insight:
Cri-Du-Chat syndrome treatment market is expected to gain market growth at a healthy CAGR in the forecast period of 2020 to 2027. Data Bridge Market Research report on global Cri-Du-Chat syndrome treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
vimarsana © 2020. All Rights Reserved.